In Aim 1, we will use existing research and expert review to develop new text and pictorial LCC warnings and test the new warnings using online experiments to identify warnings that adult LCC users perceive as most effective. The proposed study will fill critical gaps regarding which characteristics make LCC warning labels most effective and provide needed evidence on how LCC warnings influence LCC behavioral intentions. Our overarching goal is to develop effective LCC warnings that reduce cancer and other health risks.

The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.

The purpose of this research study is to understand how the monitoring of Patient-Reported Outcomes (PROs) could help improve surgical care for patients undergoing chest surgeries. PROs are symptoms directly reported by patients through the completion of a survey.

The purpose of this study is to further adapt an evidence-based, social support intervention, enCompass for rural cancer caregivers by identifying the barriers and facilitators from the perspectives of clinical staff and healthcare administrators. Results of this study will inform the development of a clinical trial.

The Improving Provider Announcement Communication Training (IMPACT) national primary care team survey aims to investigate HPV vaccine communication among a large sample of primary care team members, including physicians, physician assistants, nurse practitioners, registered nurses and medical assistants to inform future provider communication interventions.

Develop a device to measure patient preferences in the treatment of bladder cancer.

This is a study to assess patient, provider, and pharmacist perceptions of delivering FIT kits for colorectal cancer screening in pharmacy settings.

Purpose:This is a two-arm preliminary efficacy RCT in 120 participants testing a 6-week home-based walking and progressive resistance exercise program (EXCAP©®) vs. standard care on CIPN, interoception, and inflammation. Participants: This study will enroll 120 participants receiving neurotoxic chemotherapy or have completed neurotoxic chemotherapy in the past nine months (i.e., taxane-, platinum-, vinca alkaloid-, epothilone-, or proteasome inhibitor-based chemotherapy). Procedures (methods): Participants will complete questionnaires, clinical assessments, and a blood draw at two time points: pre-intervention (week 0, T1) and post-intervention (approximately week 6, T2).

Our team developed a calculator to help oncologists better estimate prognosis in patients with metastatic breast cancer (MBC). Using this information, our team developed a prognostic calculator to predict risk of death within 30 days for patients with MBC. For this information to impact care, it will have to be used in clinical practice. In order to increase the likelihood of successful adoption of the calculator into clinical practice, we will study its implementation and evaluate its impact. In this study, we will seek the input of doctors, nurses, and advance practice providers who care for patients with MBC to better understand the factors that encourage and dissuade discussion of prognosis and use of such a prognostic tool.

This project is a randomized clinical trial (study that randomly assigns participants to one arm to fairly understand outcomes) that aims to assess if information from gene expression classifier (GEC) testing is helpful for both patients and their doctors in the management of care for newly diagnosed prostate cancer patients.